Neurogene (NGNE) Expected to Announce Earnings on Monday

Neurogene (NASDAQ:NGNE) will likely be posting its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Neurogene to post earnings of ($1.40) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). On average, analysts expect Neurogene to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Neurogene Trading Down 0.7%

Shares of NGNE traded down $0.22 during mid-day trading on Monday, hitting $32.67. 16,613 shares of the company traded hands, compared to its average volume of 184,619. The stock has a market capitalization of $516.20 million, a price-to-earnings ratio of -7.19 and a beta of 1.70. The business has a 50-day moving average of $32.42 and a 200 day moving average of $25.72. Neurogene has a one year low of $15.93 and a one year high of $43.66.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Rodman & Renshaw initiated coverage on Neurogene in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price objective on the stock. Canaccord Genuity Group reduced their target price on shares of Neurogene to $180.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a report on Tuesday, June 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Friday, July 17th. Finally, UBS Group set a $70.00 target price on Neurogene in a report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $84.83.

Insider Buying and Selling

In other news, CFO Christine Mikail Cvijic sold 4,200 shares of Neurogene stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the transaction, the chief financial officer owned 84,040 shares in the company, valued at $3,036,365.20. The trade was a 4.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 19,200 shares of company stock worth $639,932. Company insiders own 11.68% of the company’s stock.

Institutional Investors Weigh In On Neurogene

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its position in Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Neurogene in the fourth quarter valued at about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares in the last quarter. Bridgeway Capital Management LLC acquired a new position in shares of Neurogene during the third quarter worth about $187,000. Finally, Wells Fargo & Company MN raised its position in Neurogene by 45.2% in the 4th quarter. Wells Fargo & Company MN now owns 11,037 shares of the company’s stock valued at $227,000 after buying an additional 3,438 shares during the last quarter. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.